Skip to Content


In the US, Daptomycin (daptomycin systemic) is a member of the drug class miscellaneous antibiotics and is used to treat Bacteremia, Endocarditis, Methicillin-Resistant Staphylococcus Aureus Infection, Skin and Structure Infection and Skin or Soft Tissue Infection.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Antibacterial: Lipopeptide

Chemical Names

N-(1-Oxodecyl)-L-tryptophyl-Lasparaginyl-L-alfa-aspartyl-L-treonylglycyl-L-ornityl-L-alfa-aspartyl-D-alanyl-L-alfa-aspartylglycyl-D-seryl-treo-3-metyl-L-alfa-glutamyl-gamma-(2-amminophenyl)-gamma-oxo-L-alfa-aminobutanoic acid epsilon1-lactone

N-decanoyl-L-tryptophyl-L-asparaginyl-Laspartyl-L-treonylglycyl-L-ornityl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-treo-3-metyl-L-glutamyl-3-antraniloyl-L-alanine,1.13-3.4-lactone (BAN)

N-decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-treonylglycyl-L-ornityl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-treo-3-metyl-L-glutamyl-3-antraniloyl-L-alanine,epsilon1-lacton (IUPAC)

N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-treonylglycyl-L-ornityl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-treo-3-metyl-L-glutamyl-3-antraniloyl-L-alanine,epsilon1-lactone (WHO)

Foreign Names

  • Daptomycinum (Latin)
  • Daptomycin (German)
  • Daptomycine (French)
  • Daptomicina (Spanish)

Generic Names

  • Daptomycin (OS: USAN, BAN, JAN)
  • LY-146032 (IS: Lilly)

Brand Names

  • Cubicin
    AstraZeneca, China; AstraZeneca, Hong Kong; AstraZeneca, Malaysia; AstraZeneca, Philippines; AstraZeneca, South Africa; AstraZeneca Singapore, Singapore; Cardinal Health, Taiwan; Cubist, Israel; Cubist, United States; Hospira Inc., Vietnam; MSD, Japan; Novartis, Argentina; Novartis, Chile; Novartis, Finland; Novartis, France; Novartis, Greece; Novartis, Croatia (Hrvatska); Novartis, Ireland; Novartis, Iceland; Novartis, Lithuania; Novartis, Norway; Novartis, New Zealand; Novartis, Poland; Novartis, Romania; Novartis, Sweden; Novartis, Slovakia; Novartis, Turkey; Novartis Europharm, Austria; Novartis Europharm, Cyprus; Novartis Europharm, Denmark; Novartis Farma, Italy; Novartis Farmaceutica, Spain; Novartis Pharma, Switzerland; Novartis Pharma, Germany; Novartis Pharmaceuticals, Australia; Novartis Pharmaceuticals UK, United Kingdom; Sunovion Pharmaceuticals, Canada; TTY Biopharm, Taiwan


BANBritish Approved Name
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.